{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:25:24Z","timestamp":1790612724428,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immune checkpoint inhibitors (ICIs) are a novel class of oncological agents which are used to treat a number of malignancies. To date seven agents have been approved by the Food and Drug Administration (FDA) to treat both solid and haematological malignancies. Despite their efficacy they have been associated with a number of endocrinopathies. We report a unique case of hypophysitis, thyroiditis, severe hypercalcaemia and pancreatitis following combined ICI therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 46-year old Caucasian female with a background history of malignant melanoma and lung metastases presented to the emergency department with lethargy, nausea, palpitations and tremors. She had been started on a combination of nivolumab and ipilimumab 24\u2009weeks earlier. Initial investigations revealed thyrotoxicosis with a thyroid stimulating hormone (TSH) of &lt;\u20090.01 (0.38\u20135.33) mIU\/L, free T4 of 66.9 (7\u201316) pmol\/.L. TSH receptor and thyroperoxidase antibodies were negative. She was diagnosed with thyroiditis and treated with a beta blocker. Six weeks later she represented with polyuria and polydipsia. A corrected calcium of 3.54 (2.2\u20132.5) mmol\/l and parathyroid hormone (PTH) of 9 (10\u201365) pg\/ml confirmed a diagnosis of non-PTH mediated hypercalcaemia. PTH-related peptide and 1, 25-dihydroxycholecalciferol levels were within the normal range. Cross-sectional imaging and a bone scan out ruled bone metastases but did reveal an incidental finding of acute pancreatitis \u2013 both glucose and amylase levels were normal. The patient was treated with intravenous hydration and zoledronic acid. Assessment of the hypothalamic-pituitary-adrenal (HPA) axis uncovered adrenocorticotrophic hormone (ACTH) deficiency with a morning cortisol of 17\u2009nmol\/L. A pituitary Magnetic Resonance Image (MRI) was unremarkable. Given her excellent response to ICI therapy she remained on ipilimumab and nivolumab. On follow-up this patient\u2019s thyrotoxicosis had resolved without anti-thyroid mediations \u2013 consistent with a diagnosis of thyroiditis secondary to nivolumab use. Calcium levels normalised rapidly and remained normal. ACTH deficiency persisted, and she is maintained on oral prednisolone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This is a remarkable case in which ACTH deficiency due to hypophysitis; thyroiditis; hypercalcaemia and pancreatitis developed in the same patient on ipilimumab and nivolumab combination therapy. We postulate that hypercalcaemia in this case was secondary to a combination of hyperthyroidism and secondary adrenal insufficiency.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-021-00693-x","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T10:03:36Z","timestamp":1614420216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature"],"prefix":"10.1186","volume":"21","author":[{"given":"Christine","family":"Newman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oratile","family":"Kgosidalwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamah A.","family":"Hakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,27]]},"reference":[{"key":"693_CR1","first-page":"15","volume":"37","author":"K Ronan","year":"2019","unstructured":"Ronan K, Othman EHS, McKenna S, Anderson C, Sheehan D, Griffin M, et al. Immunotherapy-induced endocrinopathies: a multicentre experience. J Clin Oncol. 2019;37:15.","journal-title":"J Clin Oncol"},{"key":"693_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1530\/EJE-17-0810","volume":"178","author":"ES Scott","year":"2018","unstructured":"Scott ES, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang VH. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur J Endocrinol. 2018;178:173\u201380.","journal-title":"Eur J Endocrinol"},{"key":"693_CR3","doi-asserted-by":"publisher","first-page":"6585","DOI":"10.1002\/cam4.2533","volume":"8","author":"E Kassi","year":"2019","unstructured":"Kassi E, Angelousi A, Asonitis N, Diamantopoulos P, Anastasopoulo A, Papaxoinis G, et al. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma. Cancer Med. 2019;8:6585\u201394.","journal-title":"Cancer Med"},{"key":"693_CR4","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1210\/jc.2018-00728","volume":"103","author":"K Clotman","year":"2018","unstructured":"Clotman K, Janssens K, Specenier P, Weets I, De Block CEM. Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J Clin Endocrinol Metab. 2018;103:3144\u201354.","journal-title":"J Clin Endocrinol Metab"},{"key":"693_CR5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1210\/js.2017-00170","volume":"1","author":"AC Paepegaey","year":"2017","unstructured":"Paepegaey AC, Lheure C, Ratour C, Lethielleux G, Clerc J, Bertherat J, et al. Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma. J Endocr Soc. 2017;1:646\u20139.","journal-title":"J Endocr Soc"},{"key":"693_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/CMR.0000000000000405","volume":"27","author":"K Lupu","year":"2017","unstructured":"Lupu K, Pages C, Laly P, Deylon J, Laloi M, Petit A, et al. Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination. Melanoma Reg. 2017;27:649\u201352.","journal-title":"Melanoma Reg"},{"key":"693_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1210\/jc.2017-01905","volume":"103","author":"C Zhao","year":"2018","unstructured":"Zhao C, Tella SH, Del Rivero J, Kommalapati A, Ebenuwa I, Gulley JL, et al. Anti-PD-L1 treatment induced central diabetes insipidus. J Clin Endocrinol Metab. 2018;103:365\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"693_CR8","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1210\/jc.2018-01151","volume":"104","author":"P Piranavan","year":"2019","unstructured":"Piranavan P, Li Y, Brown E, Kemp EH, Trivedi N. Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J Clin Endocrinol Metab. 2019;104:550\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"693_CR9","doi-asserted-by":"publisher","unstructured":"Tan MH, Iyengar R, Mizokami-Stout K, Yentz S, MacEachern MP, Shen LY, et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol. 2019. https:\/\/doi.org\/10.1186\/s40842-018-0073-4.","DOI":"10.1186\/s40842-018-0073-4"},{"key":"693_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Nair VS, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50:1\u201311.","journal-title":"Exp Mol Med"},{"key":"693_CR11","doi-asserted-by":"publisher","unstructured":"McGowan A, Weatherby T, Powlson A, Parkinson C, Chatterjee K, Corrie P, et al. Endocrinopathies are a frequent consequence of immune-checkpoint inhibitor therapy, with a low recover rate of both thyroid and pituitary dysfunction. Endocr Abstr. 2017. https:\/\/doi.org\/10.1530\/endoabs.50.P251.","DOI":"10.1530\/endoabs.50.P251"},{"key":"693_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/er.2004-0011","volume":"26","author":"P Caturegli","year":"2005","unstructured":"Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC, Rose NR. Autoimmune hypophysitis. Endocr Rev. 2005;26:599\u2013614.","journal-title":"Endocr Rev"},{"key":"693_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-14-0845","volume":"17","author":"F Albarel","year":"2015","unstructured":"Albarel F, Gaudy C, Castinetti F, Carre T, Morange I, Conte-Devolx B, et al. Long term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;17:195\u2013204.","journal-title":"Eur J Endocrinol"},{"key":"693_CR14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","volume":"29","author":"AV Maker","year":"2006","unstructured":"Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006;29:455\u201363.","journal-title":"J Immunother"},{"key":"693_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4:173\u201382.","journal-title":"JAMA Oncol"},{"key":"693_CR16","doi-asserted-by":"publisher","unstructured":"Levy M, Abeillon J, Borson-Chazot F, Daile S, Raverot G, Anceau CC. Immune checkpoint inhibitors therapy-induced hypophysitis is frequently associated with previous thyroid disorders: results from ImmuCare study. Endocr Abstr. 2019. https:\/\/doi.org\/10.1530\/endoabs.63.GP238.","DOI":"10.1530\/endoabs.63.GP238"},{"key":"693_CR17","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","volume":"186","author":"P Caturegli","year":"2016","unstructured":"Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Laman T, Taverna G, et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol. 2016;186:3225\u201335.","journal-title":"Am J Pathol"},{"key":"693_CR18","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99:4078\u201385.","journal-title":"J Clin Endocrinol Metab"},{"key":"693_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4137\/CMED.S22469","volume":"8","author":"M Mahzari","year":"2015","unstructured":"Mahzari M, Liu D, Arnaout A, Lochnan H. Immune checkpoint inhibitor therapy associated hypophysitis. Clin Med Insights Endocrinol Diabetes. 2015;8:21\u20138.","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"693_CR20","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s40425-019-0729-3","volume":"7","author":"S Thapi","year":"2019","unstructured":"Thapi S, Leiter A, Galsky M, Gallagher EJ. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis. J Immunother Cancer. 2019;7:248.","journal-title":"J Immunother Cancer"},{"key":"693_CR21","doi-asserted-by":"publisher","unstructured":"Girotra M, Hansen A, Farooki A, Byun DJ, Min L, Creelan BC, et al. The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectr. 2018. https:\/\/doi.org\/10.1093\/jncics\/pky021.","DOI":"10.1093\/jncics\/pky021"},{"key":"693_CR22","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1634\/theoncologist.2017-0375","volume":"23","author":"NS Patel","year":"2018","unstructured":"Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP. Incidence of thyroid function test abnormalities in patients receiving immune-checkpoint inhibitors for cancer treatment. Oncologist. 2018;23:1236\u201341.","journal-title":"Oncologist."},{"key":"693_CR23","doi-asserted-by":"publisher","unstructured":"Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, et al. Immune-related thyroiditis with checkpoint inhibitors. Thyroid. 2018. https:\/\/doi.org\/10.1089\/thy.2018.0116.","DOI":"10.1089\/thy.2018.0116"},{"key":"693_CR24","doi-asserted-by":"publisher","unstructured":"McMillen B, Dhillon MS, Yong-Yow S. A rare case of thyroid storm. BMJ Case Rep. 2016. https:\/\/doi.org\/10.1136\/bcr-2016-214603.","DOI":"10.1136\/bcr-2016-214603"},{"key":"693_CR25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.14740\/jocmr3257w","volume":"10","author":"K Takebayashi","year":"2018","unstructured":"Takebayashi K, Ujiie A, Kubo M, Furukawa S, Yamauchi M, Shinozaki H, et al. Isolated adrenocorticotropic hormone deficiency and severe hypercalcemia after destructive thyroiditis in a patient on nivolumab therapy with a malignant melanoma. J Clin Med Res. 2018;10:358\u201362.","journal-title":"J Clin Med Res"},{"key":"693_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/ERC-13-0499","volume":"21","author":"M Ryder","year":"2014","unstructured":"Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21:371\u201381.","journal-title":"Endocr Relat Cancer"},{"key":"693_CR27","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","volume":"3","author":"SH Tirumani","year":"2015","unstructured":"Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3:1185\u201392.","journal-title":"Cancer Immunol Res"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00693-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12902-021-00693-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00693-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T10:06:16Z","timestamp":1614420376000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-021-00693-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,27]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["693"],"URL":"https:\/\/doi.org\/10.1186\/s12902-021-00693-x","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,27]]},"assertion":[{"value":"21 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient provided their written consent for the publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Amar Agha, the senior author on this paper is also a member of the editorial review board of BMC Endocrine Disorders.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}